MDxHealth SA (NASDAQ:MDXH) Short Interest Up 133.8% in February

MDxHealth SA (NASDAQ:MDXH) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 31,100 shares, a growth of 133.8% from the February 13th total of 13,300 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 113,500 shares, the short-interest ratio is presently 0.3 days.

MDxHealth Price Performance

Shares of MDXH opened at $1.50 on Friday. The company has a market capitalization of $70.93 million, a P/E ratio of -0.99 and a beta of 1.37. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The firm has a 50 day moving average of $1.89 and a 200 day moving average of $2.10. MDxHealth has a twelve month low of $1.35 and a twelve month high of $3.50.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. As a group, equities research analysts anticipate that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC bought a new stake in shares of MDxHealth during the fourth quarter valued at approximately $25,000. Oppenheimer & Co. Inc. boosted its holdings in MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after purchasing an additional 10,000 shares during the last quarter. FAS Wealth Partners Inc. boosted its holdings in MDxHealth by 49.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock worth $58,000 after purchasing an additional 8,100 shares during the last quarter. XTX Topco Ltd purchased a new stake in MDxHealth in the fourth quarter worth approximately $63,000. Finally, Delta Investment Management LLC purchased a new stake in MDxHealth in the fourth quarter worth approximately $81,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.